Effect of curcumin on cisplatin- and oxaliplatin-induced oxidative stress in human embryonic kidney (HEK) 293 cells

Renal Failure

Volumn 33, Issue 5, 2011, Pages 518-523

  Waly, Mostafa I ^a   Al Moundhri, Mansour S ^a   Ali, Badreldin H ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

cisplatin; Curcumin; HEK 293 cells; oxaliplatin; oxidative stress

Indexed keywords

CATALASE; CISPLATIN; CURCUMIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; OXALIPLATIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CELL VIABILITY; CONCENTRATION RESPONSE; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MEMBRANE DAMAGE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL MEMBRANE; CELL SURVIVAL; CISPLATIN; CURCUMIN; DRUG EVALUATION, PRECLINICAL; GLUTATHIONE; HEK293 CELLS; HUMANS; KIDNEY; KIDNEY DISEASES; ORGANOPLATINUM COMPOUNDS; OXIDATIVE STRESS; PHYTOTHERAPY;

EID: 79956269845     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.577546     Document Type: Article

References (26)

1. Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatin associated nephrotoxicity and pathological events. Contrib Nephrol. 2005;148:107-121. (Pubitemid 43264925)
2. Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J Exp Clin Cancer Res. 2010;29:87.
3. Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: A review of some recent research. Food Chem Toxicol. 2006;44:1173-1183.
4. Ali BH. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: A minireview of recent literature. Basic Clin Pharmacol Toxicol. 2010;10: 272-279.
5. Raez LE, Kobina S, Santos ES. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11:18-24.
6. Kanou T, Uozumi J, Soejima K, Tokuda Y, Masaki Z. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices. Clin Exp Nephrol. 2004;8:310-315. (Pubitemid 40941106)
7. Ali BH, Marrif H, Noureldyem SA, Bakhiet AO, Blunden G. Some biological properties of curcumin. A review. Nat Prod Comm. 2006;1:509-521.
8. Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: The evidence from in vitro, animal and human studies. Br J Nutr. 2010;103:1545-1557.
9. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631-1652.
10. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anticancer agent: Review of the gap between basic and clinical applications. Curr Med Chem. 2010;17:190-197.
11. Kuhad A, Pilkhwal S, Sharma S, Tirkey N, Chopra K. Effect of curcumin on inflammation and oxidative stress in cisplatininduced experimental nephrotoxicity. J Agric Food Chem. 2007;55:10150-10155.
12. Abdel Fattah EA, Hashem HE, Ahmed FA, Ghallab MA, Varga I, Polak S. Prophylactic role of curcumin against cyclosporine-induced nephrotoxicity: Histological and immunohistological study. Gen Physiol Biophys. 2010;29: 85-94.
13. Ali BH, Al-Wabel N, Mahmoud O, Mousa HM, Hashad M. Curcumin has a palliative action on gentamicin-induced nephrotoxicity in rats. Fundam Clin Pharmacol. 2005;19: 473-477. (Pubitemid 41002418)
14. Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008;73:994-1007. (Pubitemid 351543900)
15. Lowry OH, Rosebrough NJ, Fait AL, Ramdal RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
16. Malich G, Markovic B, Winder C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology. 1997;124:179-192. (Pubitemid 28055528)
17. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;48(17):4827-4833.
18. Simpson D, Dunn C, Curran M, Goa KL.Oxaliplatin: A review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs. 2003;63:2127-2156. (Pubitemid 37229090)
19. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008;61:903-904.
20. Hanada K, Suda M, Kanai N, Ogata H. Pharmacokinetics and toxicodynamics of oxaliplatin in rats: Application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives. Pharm Res. 2010;27:1893-1899.
21. Kawazoe H, Kawazoe H, Sugishita H, et al. Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment. Gan To Kagaku Ryoho. 2010;37:1153-1157.
22. Moretto J, Chauffert B, Ghiringhelli F, Aldrich-Wright JR, Bouyer F. Discrepancy between in vitro and in vivo antitumor effect of a new platinum (II) metallointercalator. Invest New Drugs. in press.
23. Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf. 2003;2:597-607.
24. Ray B, Lahiri DK. Neuroinflammation in Alzheimer's disease: Different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol. 2009;9: 434-444.
25. Patel BB, Majumdar AP. Synergistic role of curcumin with current therapeutics in colorectal cancer: Minireview. Nutr Cancer. 2009;61:842-846.
26. Mendonça LM, Dos Santos GC, Antonucci GA, Dos Santos AC, Bianchi Mde L, Antunes LM. Evaluation of the cytotoxicity and genotoxicity of curcumin in PC12 cells. Mutat Res. 2009;675:29-34.